Your browser doesn't support javascript.
loading
[Current status of treatment of refractory ascites in patients with liver cirrhosis].
Shao, J; Zhang, L; Han, G H; Fan, D M.
Afiliação
  • Shao J; Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of the Fourth Military Medical University, Xi'an 710032, China.
Zhonghua Gan Zang Bing Za Zhi ; 24(10): 721-723, 2016 Oct 20.
Article em Zh | MEDLINE | ID: mdl-27938554
Ascites is a common clinical manifestation of cirrhotic portal hypertension, and about 60%-80% of cirrhotic patients develop the symptom of ascites within 10 years. Once ascites occurs, the 5-year survival rate is reduced from 80% to 50%. With the progression of liver diseases, approximately 5%-10% of patients with ascites develop refractory ascites, and the median survival time is only 6-12 months. This article reviews the definition and diagnosis of refractory ascites, evaluation of prognostic factors, and treatment regimens, including large-volume paracentesis combined with protein supplementation, transjugular intrahepatic portosystemic shunt, and liver transplantation.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ascite / Paracentese / Derivação Portossistêmica Transjugular Intra-Hepática / Cirrose Hepática Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans Idioma: Zh Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ascite / Paracentese / Derivação Portossistêmica Transjugular Intra-Hepática / Cirrose Hepática Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans Idioma: Zh Ano de publicação: 2016 Tipo de documento: Article